Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.6M
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
36.4M
-
Shares change
-
-247K
-
Total reported value, excl. options
-
$411M
-
Value change
-
-$2.05M
-
Put/Call ratio
-
0.11
-
Number of buys
-
26
-
Number of sells
-
-48
-
Price
-
$11.27
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q4 2022
105 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q4 2022.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.4M shares
of 54.6M outstanding shares and own 66.72% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), FMR LLC (6.11M shares), Vivo Capital, LLC (4.22M shares), ORBIMED ADVISORS LLC (2.87M shares), Logos Global Management LP (2.35M shares), BlackRock Inc. (1.7M shares), VANGUARD GROUP INC (1.43M shares), EVENTIDE ASSET MANAGEMENT, LLC (902K shares), Cormorant Asset Management, LP (612K shares), and Redmile Group, LLC (607K shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.